BRISBANE, Calif., Oct. 6, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company” or “GTB”) GTBPa clinical-stage immuno-oncology company focused on developing innovative therapeutics based on the company’s natural killer (NK) cell attacher, TriKE® Platform, today announced two poster presentations at the 37th Annual Society for Immunotherapy of Cancer Meeting (SITC 2022), to be held November 8-12, 2022 in Boston, Massachusetts and virtually. The two posters will highlight preclinical data on Tri-Specific NK cell attackers for the treatment of mesothelioma and prostate cancer.
poster presentations
Title: Tri-specific killer engagers target natural killer cells against mesothelioma
Abstract number: 1202
moderator: Pippa Kennedy and Martin Felices
date: November 11, 2022
Place and time: Poster Hall from 9:00 a.m. to 8:30 p.m. ET
Title: Improving NK cell function in the “cold” tumor microenvironment of prostate cancer with a novel tri-specific killer engager against prostate-specific membrane antigen (PSMA)
Abstract number: 1204
moderator: Shee Kwan Phung and Martin Felices
date: November 11, 2022
Place and time: Poster Hall from 9:00 a.m. to 8:30 p.m. ET
About SITC
Founded in 1984, the Society for Immunotherapy of Cancer (SITC) is a not-for-profit organization of healthcare professionals dedicated to improving cancer patient outcomes by advancing the development, science, and application of cancer immunotherapy and tumor immunology. SITC is made up of influential basic and translational scholars, practitioners, health professionals, government leaders and industry experts from around the world. Through educational initiatives that encourage scientific exchange and collaboration among leaders in the field, SITC hopes to one day make the word “cure” a reality for cancer patients around the world. Learn more about SITC at sitcancer.org.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and…
